Skip to content

Author

P. Barrios

We have 3 of 19 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

49 Effect of Co-Morbidity Burden on the Efficacy and Tolerability of Belzutifan in Patients with Metastatic Renal Cell Carcinoma

Abstract Background Belzutifan, a hypoxia-inducible factor-2α (HIF-2α) inhibitor, has demonstrated efficacy in advanced clear-cell renal cell carcinoma (ccRCC) in patients previously received immunotherapy (IO) and anti-angiogenics. However, comorbidities pose a challenge in cancer management and often limit inclusion...

Ali Hajj Ali, Liliana Ascione, R. Nawfal et al. · 0 citations
Open access Sep 2026

72 Time-of-day of Immune Checkpoint Inhibitor Infusion and Overall Survival in Renal Cell Carcinoma: A Real-World Cohort Analysis

Abstract Background Previous retrospective work found an association between earlier immune-checkpoint inhibitors (ICI) infusion times and survival outcomes in renal cell carcinoma (RCC). A recent randomized trial in non-small cell lung cancer (NSCLC) also reported benefit, however, a recent analysis of several randomi...

P. Barrios, Mustafa Saleh, Liliana Ascione et al. · 0 citations
Open access Sep 2026

75 Transcriptional Correlates of ARNT Expression and its Impact on Survival Outcomes in Clear-Cell Renal Cell Carcinoma (ccRCC)

Across three cohorts, higher ARNT expression correlated with higher BHS, and a consistent correlation was observed between ARNT and EPAS1 and HIF1A expressions, and a consistent correlation was observed between ARNT and EPAS1 expressions.

Wassim Daoud Khatoun, Ali Hajj Ali, Eddy Saad et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.